These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20006889)

  • 1. Editorial comment.
    Kibel AS
    J Urol; 2010 Feb; 183(2):533; discussion 533. PubMed ID: 20006889
    [No Abstract]   [Full Text] [Related]  

  • 2. The ultimate prostate cancer biopsy decision support tool.
    Kattan MW; Jones JS
    Eur Urol; 2010 Jan; 57(1):9-10; discussion 10-11. PubMed ID: 19720450
    [No Abstract]   [Full Text] [Related]  

  • 3. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    Nguyen CT; Yu C; Moussa A; Kattan MW; Jones JS
    J Urol; 2010 Feb; 183(2):529-33. PubMed ID: 20006887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
    Chun FK; Briganti A
    Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.
    Rabbani F
    Eur Urol; 2007 Sep; 52(3):723-4. PubMed ID: 17337115
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Shariat SF; Svatek RS
    Eur Urol; 2009 Mar; 55(3):626-8. PubMed ID: 18499336
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment on: Erectile function in prostate cancer-free patients who underwent prostate saturation biopsy.
    Badalyan R
    Eur Urol; 2008 Mar; 53(3):545-6. PubMed ID: 17619080
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimizing prostate biopsy techniques.
    Kibel AS
    J Urol; 2007 Jun; 177(6):1976-7. PubMed ID: 17509275
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment.
    Merseburger AS
    J Urol; 2009 Oct; 182(4):1356. PubMed ID: 19683268
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment.
    Damodaran C
    J Urol; 2009 Oct; 182(4):1356. PubMed ID: 19683288
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kattan MW
    Eur Urol; 2008 Sep; 54(3):611. PubMed ID: 18207318
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
    Philip J
    Eur Urol; 2008 May; 53(5):981-2. PubMed ID: 17997013
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Hakenberg OW
    Eur Urol; 2009 Feb; 55(2):421. PubMed ID: 19027224
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
    Patel A
    Eur Urol; 2008 May; 53(5):982-3. PubMed ID: 17997023
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Rittmaster R
    Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
    [No Abstract]   [Full Text] [Related]  

  • 16. [PSA level--is 4.0 ng/ml as upper limit too high].
    Aktuelle Urol; 2005 Jun; 36(3):181-8. PubMed ID: 16001334
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Joniau S
    Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Scattoni V
    Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
    [No Abstract]   [Full Text] [Related]  

  • 19. Transrectal fine-needle aspiration and truecut needle biopsy of the prostate: a blinded comparison of accuracy.
    Klotz LH; Shaw PA; Srigley JR
    Can J Surg; 1989 Jul; 32(4):287-9. PubMed ID: 2660974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment.
    Parsons JK
    J Urol; 2009 Oct; 182(4):1340-1; discussion 1341. PubMed ID: 19683271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.